MM Park, AL Davis, NW Schluger, H Cohen and WN Rom
Department of Medicine, New York University Medical Center, New York, USA.

We analyzed the clinical and laboratory findings and outcome of 173 patients hospitalized at our institution from 1983 to 1994 with multidrug-resistant tuberculosis (MDR-TB) and evaluated outcome. The 173 patients (mean age 40 +/- 1 yr) were predominantly male (92%), African American or Hispanic (80%), and mostly undomiciled. Over half (52%) were known to be HIV-infected. HIV-positive MDR-TB patients had significantly more pulmonary and constitutional symptoms, more extrapulmonary disease, and fewer cavitary lesions on chest radiographs. Fifty-five percent of the patients in the cohort have died; mortality was significantly greater for HIV-positive than HIV- negative (72% versus 20%, p < 0.01). The median duration of survival of MDR-TB patients was 22 +/- 1 mo. Overall, extrapulmonary involvement was a risk factor for shorter survival, while a cavitary lesion on initial chest film and institution of appropriate treatment were positive predictors of survival. In HIV+ patients, only appropriate therapy was associated with prolonged survival (median of 14.1 mo). Interestingly, there was a trend toward better outcome in the first half of the decade reviewed. We conclude that although mortality from MDR-TB is high in both HIV-positive and HIV-negative patients, institution of appropriate therapy is the factor most strongly associated with a favorable outcome. Development of new diagnostic and therapeutic strategies for MDR-TB are urgently needed.

This article has been cited by other articles:

				R. Condos, N. Hadgiangelis, E. Leibert, G. Jacquette, T. Harkin, and W. N. Rom Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis Chest, July 1, 2008; 134(1): 187 - 192. [Abstract] [Full Text] [PDF]

				N. Parrish, G. Osterhout, K. Dionne, A. Sweeney, N. Kwiatkowski, K. Carroll, K. C. Jost Jr., and J. Dick Rapid, Standardized Method for Determination of Mycobacterium tuberculosis Drug Susceptibility by Use of Mycolic Acid Analysis J. Clin. Microbiol., December 1, 2007; 45(12): 3915 - 3920. [Abstract] [Full Text] [PDF]

				N. W. Schluger Tuberculosis drug resistance in Europe: sunny days, but clouds on the horizon? Eur. Respir. J., November 1, 2007; 30(5): 825 - 827. [Full Text] [PDF]

				S. K. Sharma and A. Mohan Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest, July 1, 2006; 130(1): 261 - 272. [Abstract] [Full Text] [PDF]

				C. Piersimoni, A. Olivieri, L. Benacchio, and C. Scarparo Current Perspectives on Drug Susceptibility Testing of Mycobacterium tuberculosis Complex: the Automated Nonradiometric Systems J. Clin. Microbiol., January 1, 2006; 44(1): 20 - 28. [Full Text] [PDF]

				M Ruddy, Y Balabanova, C Graham, I Fedorin, N Malomanova, E Elisarova, S Kuznetznov, G Gusarova, S Zakharova, A Melentyev, et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia Thorax, February 1, 2005; 60(2): 130 - 135. [Abstract] [Full Text] [PDF]

				D. A. J. Moore, D. Mendoza, R. H Gilman, C. A. W. Evans, M.-G. Hollm Delgado, J. Guerra, L. Caviedes, D. Vargas, E. Ticona, J. Ortiz, et al. Microscopic Observation Drug Susceptibility Assay, a Rapid, Reliable Diagnostic Test for Multidrug-Resistant Tuberculosis Suitable for Use in Resource-Poor Settings J. Clin. Microbiol., October 1, 2004; 42(10): 4432 - 4437. [Abstract] [Full Text] [PDF]

				G. Di Perri and S. Bonora Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J. Antimicrob. Chemother., September 1, 2004; 54(3): 593 - 602. [Abstract] [Full Text] [PDF]

				R. Condos, F. P. Hull, N. W. Schluger, W. N. Rom, and G. C. Smaldone Regional Deposition of Aerosolized Interferon-{gamma} in Pulmonary Tuberculosis Chest, June 1, 2004; 125(6): 2146 - 2155. [Abstract] [Full Text] [PDF]

				E. D. Chan, V. Laurel, M. J. Strand, J. F. Chan, M.-L. N. Huynh, M. Goble, and M. D. Iseman Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis Am. J. Respir. Crit. Care Med., May 15, 2004; 169(10): 1103 - 1109. [Abstract] [Full Text] [PDF]

				D Shitrit, D Bendayan, M Saute, and M R Kramer Multidrug resistant tuberculosis following lung transplantation: treatment with pulmonary resection Thorax, January 1, 2004; 59(1): 79 - 80. [Abstract] [Full Text] [PDF]

				C. Mitnick, J. Bayona, E. Palacios, S. Shin, J. Furin, F. Alcantara, E. Sanchez, M. Sarria, M. Becerra, M. C. S. Fawzi, et al. Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, Peru N. Engl. J. Med., January 9, 2003; 348(2): 119 - 128. [Abstract] [Full Text] [PDF]

				F Drobniewski, I Eltringham, C Graham, J G Magee, E G Smith, and B Watt A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK Thorax, September 1, 2002; 57(9): 810 - 816. [Abstract] [Full Text] [PDF]

				M. Bashar, P. Alcabes, W. N. Rom, and R. Condos Increased Incidence of Multidrug-Resistant Tuberculosis in Diabetic Patients on the Bellevue Chest Service, 1987 to 1997 Chest, November 1, 2001; 120(5): 1514 - 1519. [Abstract] [Full Text] [PDF]

				T. F. Brewer, S. J. Heymann, S. M. Krumplitsch, M. E. Wilson, G. A. Colditz, and H. V. Fineberg Strategies to Decrease Tuberculosis in US Homeless Populations: A Computer Simulation Model JAMA, August 15, 2001; 286(7): 834 - 842. [Abstract] [Full Text] [PDF]

				M. Narita, P. Alonso, M. Lauzardo, E. S. Hollender, A. E. Pitchenik, and D. Ashkin Treatment Experience of Multidrug-Resistant Tuberculosis in Florida, 1994-1997 Chest, August 1, 2001; 120(2): 343 - 348. [Abstract] [Full Text] [PDF]

				M. d. L. Garcia-Garcia, A. Ponce-de-Leon, M. E. Jimenez-Corona, A. Jimenez-Corona, M. Palacios-Martinez, S. Balandrano-Campos, L. Ferreyra-Reyes, L. Juarez-Sandino, J. Sifuentes-Osornio, H. Olivera-Diaz, et al. Clinical Consequences and Transmissibility of Drug-Resistant Tuberculosis in Southern Mexico Arch Intern Med, March 13, 2000; 160(5): 630 - 636. [Abstract] [Full Text] [PDF]

				W. W. Yew, C. K. Chan, C. H. Chau, C. M. Tam, C. C. Leung, P. C. Wong, and J. Lee Outcomes of Patients With Multidrug-Resistant Pulmonary Tuberculosis Treated With Ofloxacin/Levofloxacin-Containing Regimens Chest, March 1, 2000; 117(3): 744 - 751. [Abstract] [Full Text] [PDF]

				F.A. DROBNIEWSKI, S.A. WATTERSON, S.M. WILSON, and G.S. HARRIS A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis J. Med. Microbiol., March 1, 2000; 49(3): 271 - 278. [Abstract] [Full Text] [PDF]

				M. FLAMENT-SAILLOUR, J. ROBERT, V. JARLIER, and J. GROSSET Outcome of Multi-drug-resistant Tuberculosis in France . A Nationwide Case-Control Study Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 587 - 593. [Abstract] [Full Text]

				D. V. Havlir and P. F. Barnes Tuberculosis in Patients with Human Immunodeficiency Virus Infection N. Engl. J. Med., February 4, 1999; 340(5): 367 - 373. [Full Text] [PDF]

				L. SANDMAN, N. W. SCHLUGER, A. L. DAVIDOW, and S. BONK Risk Factors for Rifampin-monoresistant Tuberculosis . A Case-Control Study Am. J. Respir. Crit. Care Med., February 1, 1999; 159(2): 468 - 472. [Abstract] [Full Text]

				K. M. Chan-Tack, J. F. Diaz, W. A. Geerligs, R. van Altena, T. S. van der Werf, A. Pablos-Mendez, M. C. Raviglione, and P. Nunn Antituberculosis-Drug Resistance N. Engl. J. Med., October 8, 1998; 339(15): 1079 - 1080. [Full Text]

				N. W. SCHLUGER and W. N. ROM The Host Immune Response to Tuberculosis Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 679 - 691. [Full Text] [PDF]